Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.
The drugmaker’s Denmark-listed shares were up 3.3%.
Novo said the drug appeared safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects. The company plans to start late-stage trials in 2026.
Amycretin, Novo’s next-generation obesity drug, has a dual-mode action, targeting the gut hormone GLP-1 and a pancreatic hormone called amylin.
The data further validates the potential best-in-class profile of amycretin, said Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk.
